About Neurovance
Neurovance is a company based in Cambridge (United States) founded in 2011 was acquired by Otsuka in March 2017. Neurovance has raised $53.03 million across 6 funding rounds from investors including Otsuka, Tekla Capital Management and Venture Investors. The company has 7 employees as of December 31, 2016. Neurovance operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Cambridge, United States
- Employees 7 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Neurovance
Unlock access to complete
Leadership Team
27 people
Data Analysis and Operations Team
24 people
Software Development Team
16 people
Human Resources and Administration
13 people
Operations Team
9 people
Sales and Marketing
8 people
Senior Team
8 people
Legal and Compliance
8 people
Unlock access to complete
Funding Insights of Neurovance
Neurovance has successfully raised a total of $53.03M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $554.28 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neurovance
Neurovance has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Otsuka, Tekla Capital Management and Venture Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Neurovance
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurovance
Investment portfolio details for Neurovance
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neurovance
Detailed financials for Neurovance
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurovance Comparisons
Peer comparison for Neurovance
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neurovance
Neurovance operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
Detailed competitors of Neurovance
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurovance
Complete news archive for Neurovance
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurovance
Neurovance was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Neurovance is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Neurovance is a funded company, having raised a total of $53.03M across 6 funding rounds to date.
As of Dec 31, 2016, the latest employee count at Neurovance is 7.
Neurovance was established in 2011 in Cambridge, United States, as a clinical-stage company in the neuroscience sector. Centanafadine, a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin, is advanced for adult ADHD management. An extended-release formulation of this compound is under development for adolescent and pediatric ADHD to support improvements in attention and executive function.
Neurovance's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Neurovance has 6 investors. Key investors include Otsuka, Tekla Capital Management, Venture Investors, GBS, and Novartis Venture Fund.